Our research group develops and applies advanced bioanalytical strategies at the interface of forensic science, clinical pharmacology, and translational research, bridging methodological innovation with forensic and clinical application. A central focus of our work is the development of regulatory-compliant mass spectrometry methods for the identification and quantification of drugs, metabolites, and biomarkers in biological matrices such as capillary and venous blood, urine, hair, and solid tissues. These methods support the investigation of drug and xenobiotic ADME processes and the identification of biomarkers of intake. We engineer minimally invasive microsampling tools for use in roadside forensic casework and for at-home sampling in personalized monitoring, thereby expanding access to robust blood-based measurements. By integrating genotyping and phenotyping approaches, we aim to better understand inter-individual variability driven by genetic and environmental factors. Our translational research spans in vitro metabolism studies, as well as preclinical and clinical PK/PD investigations, with a particular focus on cannabinoids and emerging psychoactive substances. Embedded within the Institute of Forensic Medicine and closely connected to clinical partners, our research bridges fundamental pharmacological research with routine forensic analysis. Ultimately, we seek to advance evidence-based interpretation, support personalized medicine, and develop novel biomarkers that can inform both forensic casework and clinical practice.